SPA
OCUL icon

Sherbrooke Park Advisers’s Ocular Therapeutix OCUL Stock Holding History

Sherbrooke Park Advisers’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$125K Buy
+10,269
New +$125K 0.32% 118
2024
Q4 		– Sell
-22,649
Closed -$197K – 1049
2024
Q3 		$197K Buy
+22,649
New +$187K 0.05% 762
2024
Q1 		– Sell
-19,058
Closed -$85K – 953
2023
Q4 		$85K Buy
+19,058
New +$56.4K 0.04% 413

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sherbrooke Park Advisers's OCUL Position: Q4 2025 in Review

Sherbrooke Park Advisers opened a new position in Ocular Therapeutix (OCUL) in Q4 2025: 10,269 shares worth $125K. The stake represents 0.32% of the portfolio and ranks #118 among its holdings. This is a return to the name: Sherbrooke Park Advisers previously reported a position in OCUL as recently as Q3 2024.

Sherbrooke Park Advisers first reported a position in OCUL in Q4 2023 and has held it in 3 quarters since. The position peaked at $197K in Q3 2024. 249 funds tracked by Wall St. Rank hold OCUL as of Q4 2025.

  • Sherbrooke Park Advisers held 10,269 shares of Ocular Therapeutix worth $125K as of Q4 2025.
  • Ocular Therapeutix was a new Sherbrooke Park Advisers position in Q4 2025.
  • Ocular Therapeutix made up 0.32% of Sherbrooke Park Advisers's portfolio in Q4 2025, its #118 holding.
  • Sherbrooke Park Advisers first reported a position in Ocular Therapeutix in Q4 2023 and has held it in 3 quarters since.
  • Sherbrooke Park Advisers's Ocular Therapeutix position peaked at $197K in Q3 2024.
  • 249 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.